METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Clinical trials for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER explained in plain language.
Never miss a new study
Get alerted when new METASTATIC CASTRATION-RESISTANT PROSTATE CANCER trials appear
Sign up with your email to follow new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Early-Stage trial tests re-engineered immune cells against tough prostate cancers
Disease control TerminatedThis early-stage study tested whether a patient's own immune cells could be modified in a lab to recognize and attack advanced prostate cancer. The treatment, called BPX-601, involved collecting a patient's T-cells, engineering them to target a specific marker on cancer cells, an…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New hope for Tough-to-Treat prostate cancer?
Disease control TerminatedThis study tested several new drug combinations for men with advanced prostate cancer that had spread and was no longer responding to standard hormone therapy. The main goals were to find safe doses and see if the treatments could help control the cancer. The trial was terminated…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: Amgen • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
Targeted drug combo tested for Tough-to-Treat cancers
Disease control TerminatedThis study tested a drug called zenocutuzumab, combined with other cancer medications, for people with two specific advanced cancers. It aimed to see if the combinations could help control tumors in patients with a certain genetic change (NRG1+) in their lung cancer or in men who…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Merus B.V. • Aim: Disease control
Last updated Mar 18, 2026 14:41 UTC
-
New 'T-Cell Engager' drug tested in men with Tough-to-Treat prostate cancer
Disease control TerminatedThis was an early safety study for a new drug called acapatamab, designed to help the body's own immune cells attack advanced prostate cancer. It involved 212 men whose cancer had spread and was no longer responding to standard hormone and chemotherapy treatments. The main goal w…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Amgen • Aim: Disease control
Last updated Feb 19, 2026 14:36 UTC